ZSAN - Zosano Pharma Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9200
-0.0300 (-1.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9500
Open1.9200
Bid1.8800 x 1300
Ask1.9400 x 900
Day's Range1.8800 - 1.9473
52 Week Range1.4100 - 6.6500
Volume104,920
Avg. Volume286,024
Market Cap34.028M
Beta (3Y Monthly)3.86
PE Ratio (TTM)N/A
EPS (TTM)-2.8060
Earnings DateNov 12, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Zosano Pharma Announces CEO Transition

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical executive, will become president and chief executive officer of Zosano effective October 21, 2019.

  • GlobeNewswire

    Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100,000 shares of Zosano’s common stock to a new employee as an inducement award. The stock option has an exercise price of $1.69 per share, which is equal to the closing price of Zosano’s common stock on September 25, 2019.  25% of the shares underlying the option will vest one year after the employee’s start date, and 1/48th of the total shares will vest monthly thereafter, subject to continued service. Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on developing products where rapid administration of established molecules with established safety and efficacy profiles may provide an increased benefit to patients, for markets where patients remain underserved by existing therapies.

  • GlobeNewswire

    Zosano Pharma to Present at the Cantor Global Healthcare Conference

    FREMONT, Calif., Sept. 26, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.

  • GlobeNewswire

    Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice president of business development. “We are pleased to welcome Dushyant, who brings over 20 years of experience as a senior executive in the life sciences industry, to Zosano,” said John Walker, chairman and chief executive officer of Zosano. Dr. Pathak was most recently the associate vice chancellor of research, innovation and technology commercialization, as well as the executive director of Venture Catalyst, for the University of California Davis.

  • GlobeNewswire

    Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced an oral presentation and two poster presentations of positive data from a one-year long-term safety study of Qtrypta™ for the acute treatment of migraine were presented at the 19th Congress of the International Headache Society (IHC) in Dublin, Ireland. The Qtrypta long-term safety study was an open-label trial evaluating the safety of a 3.8 mg dose of intracutaneous zolmitriptan in adults with migraine who had historically experienced at least 2 migraine attacks per month.

  • Thomson Reuters StreetEvents

    Edited Transcript of ZSAN earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Q2 2019 Zosano Pharma Corp Earnings Call

  • GlobeNewswire

    Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

    FREMONT, Calif., Sept. 03, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.

  • GlobeNewswire

    Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

    Oral presentation of the safety and efficacy of QtryptaTM in a long-term safety study for the acute treatment of migraine.Poster on the results of patients’ freedom from pain.

  • GlobeNewswire

    Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    FREMONT, Calif., Aug. 14, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter.

  • GlobeNewswire

    Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2/3 Clinical Trial for C213 in patients with Cluster Headache. C213, for the treatment of cluster headache, consists of the company’s investigational proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM technology, which consists of titanium microneedles coated with drug, and is the same formulation as Qtrypta, for the acute treatment of migraine.

  • GuruFocus.com

    Aisling Capital Management LP Buys Zosano Pharma Corp

    Investment company Aisling Capital Management LP (Current Portfolio) buys Zosano Pharma Corp during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Aisling Capital Management LP. Continue reading...

  • GlobeNewswire

    Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update

    FREMONT, Calif., Aug. 07, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and.

  • Read This Before Selling Zosano Pharma Corporation (NASDAQ:ZSAN) Shares
    Simply Wall St.

    Read This Before Selling Zosano Pharma Corporation (NASDAQ:ZSAN) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Benzinga

    Zosano Pharma Presents Positive Migraine-ACT Results

    Zosano Pharma Corp  (NASDAQ: ZSAN ) shared positive results of Migraine-ACT scores for Qtrypta therapy. The results were presented at the AHS 61st Annual Scientific Meeting. The study assessed the effectiveness ...

  • GlobeNewswire

    Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of Migraine-ACT scores for Qtrypta™ therapy used over 6-12 months. The Migraine Assessment of Current Therapy (or Migraine-ACT) questionnaire is a standardized evaluation completed by patients to assess the effectiveness of a patient’s acute treatment of migraine therapy, with the highest achievable score being a four. At their 48-week visit, 89% of participants scored greater than three on the Migraine-ACT questionnaire, while more than 75% scored a four out of four, suggesting optimal acute treatment and no need to change that treatment.

  • In Search of That 'Tenbagger'
    TheStreet.com

    In Search of That 'Tenbagger'

    Here are 2 stocks worthy of small positions within a well-diversified biotech portfolio for aggressive investors.

  • GlobeNewswire

    Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous Microneedle Delivery System for the Acute Treatment of Migraine” at the Pharmaceutics & Advanced Drug Delivery Systems Conference in Paris on July 5, 2019 at 09:15 am CET. Ms. Lewis’ presentation will review Zosano’s novel and proprietary technology platform, the chemistry, manufacturing, and controls of the company’s lead asset, Qtrypta.

  • GlobeNewswire

    Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting

    FREMONT, Calif., July 01, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing.

  • GlobeNewswire

    Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has completed manufacturing of site qualification batches at its commercial manufacturing site for Qtrypta, the company’s investigational treatment for migraines in late stage development.  These batches are intended to demonstrate the robustness and reproducibility of the manufacturing process which will be included as part of its planned submission of a New Drug Application (NDA) for Qtrypta in the fourth quarter 2019. "The completion of these site qualification batches forms the basis of our commercial manufacturing process in our NDA and illustrates the scalability of the process as we head toward commercialization activities for Qtrypta at Thermo Fischer, in North Carolina,” said Hayley Lewis, senior vice president, operations at Zosano.

  • GlobeNewswire

    Zosano Pharma Reports First Quarter 2019 Financial Results

    Multiple catalysts, including QtryptaTM NDA submission, anticipated in 2019Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM.

  • ACCESSWIRE

    Zosano Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Zosano Pharma Corp. (NASDAQ: ZSAN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern ...

  • GlobeNewswire

    Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase additional shares in connection with Zosano’s previously announced public offering of common stock. A total of 5,750,000 shares of common stock have now been sold by Zosano in the offering, resulting in net proceeds to Zosano of approximately $18.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Zosano. As previously announced, Zosano intends to use the net proceeds from the offering to fund its ongoing development and preparation for potential commercialization of Qtrypta™ (M207), and for working capital and general corporate purposes.

  • GlobeNewswire

    Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and provide an operational update. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.

  • Zosano Pharma Corporation (NASDAQ:ZSAN): Immense Growth Potential?
    Simply Wall St.

    Zosano Pharma Corporation (NASDAQ:ZSAN): Immense Growth Potential?

    In December 2018, Zosano Pharma Corporation (NASDAQ:ZSAN) announced its latest earnings update, which showed that losses became smaller relative to the prior year's level as a result of recent tailwi...

  • GlobeNewswire

    Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain

    In this analysis, researchers reviewed eight published trials designed in accordance with the Guidance for Industry, “Migraine: Developing Drugs for Acute Treatment”, finalized in February 2018, that recommended using co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) at 2-hours post-treatment. Using the placebo response rates from these various trials, the authors were able to calculate required sample sizes for future trials and compare these calculations to the sample sizes actually used in completed trials.